Covid19 — Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
Citation(s)
Andersen CU, Markvardsen LH, Hilberg O, Simonsen U Pulmonary apelin levels and effects in rats with hypoxic pulmonary hypertension. Respir Med. 2009 Nov;103(11):1663-71. doi: 10.1016/j.rmed.2009.05.011. Epub 2009 Jun 17.
Berthiaume Y, Lesur O, Dagenais A Treatment of adult respiratory distress syndrome: plea for rescue therapy of the alveolar epithelium. Thorax. 1999 Feb;54(2):150-60. doi: 10.1136/thx.54.2.150. No abstract available.
He L, Xu J, Chen L, Li L Apelin/APJ signaling in hypoxia-related diseases. Clin Chim Acta. 2015 Dec 7;451(Pt B):191-8. doi: 10.1016/j.cca.2015.09.029. Epub 2015 Oct 3.
Herold S, Gabrielli NM, Vadasz I Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2013 Nov 15;305(10):L665-81. doi: 10.1152/ajplung.00232.2013. Epub 2013 Sep 13.
Imai Y, Kuba K, Penninger JM The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008 May;93(5):543-8. doi: 10.1113/expphysiol.2007.040048. Epub 2008 Apr 10.
Jia H Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock. 2016 Sep;46(3):239-48. doi: 10.1097/SHK.0000000000000633.
Keidar S, Kaplan M, Gamliel-Lazarovich A ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007 Feb 1;73(3):463-9. doi: 10.1016/j.cardiores.2006.09.006. Epub 2006 Sep 19.
Lesur O, Arsalane K, Lane D Lung alveolar epithelial cell migration in vitro: modulators and regulation processes. Am J Physiol. 1996 Mar;270(3 Pt 1):L311-9. doi: 10.1152/ajplung.1996.270.3.L311.
Lesur O, Hermans C, Chalifour JF, Picotte J, Levy B, Bernard A, Lane D Mechanical ventilation-induced pneumoprotein CC-16 vascular transfer in rats: effect of KGF pretreatment. Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L410-9. doi: 10.1152/ajplung.00384.2001. Epub 2002 Oct 25.
Lu W, Zhang S, Chen B, Chen J, Xian J, Lin Y, Shan H, Su ZZ A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound. Ultraschall Med. 2020 Jun;41(3):300-307. doi: 10.1055/a-1154-8795. Epub 2020 Apr 15.
Siddiquee K, Hampton J, McAnally D, May L, Smith L The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol. 2013 Mar;168(5):1104-17. doi: 10.1111/j.1476-5381.2012.02192.x.
Ware LB, Matthay MA The acute respiratory distress syndrome. N Engl J Med. 2000 May 4;342(18):1334-49. doi: 10.1056/NEJM200005043421806. No abstract available.
Wevers BA, van der Hoek L Renin-angiotensin system in human coronavirus pathogenesis. Future Virol. 2010 Mar;5(2):145-161. doi: 10.2217/fvl.10.4. Epub 2010 Mar 1.
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3. No abstract available.
Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 2004 Dec;11(23):1703-12. doi: 10.1038/sj.gt.3302339.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.